|Articles|January 18, 2022
Support for Title 21 CFR Part 11 and Annex 11 Compliance
Author(s)Agilent
This paper describes the requirements for electronic records and electronic signatures for regulated pharmaceutical organizations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
Green Chemistry’s Role in Advancing US Chemical Innovation
2
Next-Generation Modalities Drive New Antibody Discovery
3
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
4
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
5